Pyoderma gangrenosum
Pyoderma gangrenosum nyaéta kasakit kulit radang anu langka dimana pustula nyeri atanapi nodul janten borok anu ngembang sacara bertahap. Pyoderma gangrenosum henteu tepa. Pangobatan tiasa kalebet kortikosteroid, cyclosporin, atanapi sababaraha antibodi monoklonal. Sanaos tiasa mangaruhan jalma tina sagala umur, éta biasana mangaruhan jalma umur 40an sareng 50an.
☆ Dina hasil Stiftung Warentest 2022 ti Jerman, kapuasan konsumen sareng ModelDerm ngan ukur langkung handap tibatan konsultasi telemedicine anu mayar.
Dina leg hiji jalma kalawan colitis ulcerative.
References
Pyoderma gangrenosum mangrupikeun kaayaan kulit anu jarang anu nyababkeun borok nyeri sareng ujung beureum atanapi wungu. Ieu digolongkeun kana kasakit radang sarta mangrupa bagian ti grup disebut dermatoses neutrophilic. Anu ngabalukarkeun pyoderma gangrenosum kompleks, ngalibatkeun masalah sareng kekebalan bawaan sareng adaptif dina jalma anu rawan genetik. Anyar, peneliti geus fokus kana follicule bulu salaku titik awal poténsi kasakit.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum mangrupikeun kaayaan kulit anu jarang nyababkeun borok anu nyeri pisan. Sanaos urang henteu ngartos panyababna, urang terang yén éta ngalibatkeun paningkatan kagiatan sél imun anu tangtu. Ngubaran panyakit henteu gampang. Urang ngagaduhan rupa-rupa ubar anu ngirangan sistem imun atanapi ngarobih kagiatanana. Salian ieu, urang ogé museurkeun kana ngubaran tatu sareng ngatur nyeri. Corticosteroids sareng cyclosporine sering janten pilihan anu pangheulana pikeun pengobatan, tapi akhir-akhir ieu, langkung seueur panalungtikan ngeunaan ngagunakeun terapi biologis sapertos sambetan TNF-α. Biologics ieu beuki pikaresep, utamana dina penderita kaayaan radang lianna, sarta aranjeunna nuju dipake saméméhna dina prosés kasakit.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
